DRUG TRANSPORT IN THE BRAIN - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 458

315. Korshunov A, Golanov A, Sycheva R, Pronin I. 1999. Prognostic value of tumour
associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis
of 168 cases. J Clin Pathol 52:574-580.
316. Abe T, Mori T, Wakabayashi Y, Nakagawa M, Cole SP, Koike K, Kuwano M, Hori
S. 1998. Expression of multidrug resistance protein gene in patients with glioma after
chemotherapy. J Neurooncol 40:11-18.
317. Decleves X, Fajac A, Lehmann-Che J, Tardy M, Mercier C, Hurbain I, Laplanche JL,
Bernaudin JF, Scherrmann JM. 2002. Molecular and functional MDR1-Pgp and MRPs
expression in human glioblastoma multiforme cell lines. Int J Cancer 98:173-180.
318. Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, Scheper
RJ, van der Valk P, Leenstra S, Baayen JC, Spliet WG, Troost D. 2005. Localization of
breast cancer resistance protein (BCRP) in microvessel endothelium of human control
and epileptic brain. Epilepsia 46:849-857.
319. Fisher GA, Lum BL, Hausdorff J, Sikic BI. 1996. Pharmacological considerations in the
modulation of multidrug resistance. Eur J Cancer 32A:1082-1088.
320. Mohri M, Nitta H, Yamashita J. 2000. Expression of multidrug resistance-associated
protein (MRP) in human gliomas. J Neurooncol 49:105-115.
321. van Zanden JJ, de Mul A, Wortelboer HM, Usta M, van Bladeren PJ, Rietjens IM,
Cnubben NH. 2005. Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine
resistance by the flavonoid myricetin. Biochem Pharmacol 69:1657-1665.
322. Bronger H, K onig J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler
D, Nies AT. 2005. ABCC drug efflux pumps and organic anion uptake transporters in
human gliomas and the blood-tumor barrier. Cancer Res 65:11419-11428.
323. Persidsky Y, Gendelman HE. 2003. Mononuclear phagocyte immunity and the

neuropathogenesis of HIV-1 infection. J Leukoc Biol 74:691-701.
324. Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA. 2005. HIV-1 infection
and AIDS: consequences for the central nervous system. Cell Death Differ 12(Suppl
1):878-892.
325. Navia BA, Jordan BD, Price RW. 1986. The AIDS dementia complex: I. Clinical
features. Ann Neurol 19:517-524.
326. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT,
Cohen B, McArthur JC. 2001. HIV-associated neurologic disease incidence changes:
Multicenter AIDS Cohort Study, 1990-1998. Neurology 56:257-260.
327. McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, Sacktor N. 2003.
Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol
9:205-221.
328. McArthur JC. 2004. HIV dementia: an evolving disease. J Neuroimmunol 157:3-10.
329. Ruibal-Ares BH, Belmonte L, Bare PC, Parodi CM, Massud I, de Bracco MM. 2004.
HIV-1 infection and chemokine receptor modulation. Curr HIV Res 2:39-50.
330. Sukhai M, Yong A, Pak A, Piquette-Miller M. 2001. Decreased expression of P-
glycoprotein in interleukin-1beta and interleukin-6 treated rat hepatocytes. Inflamm Res
50:362-370.
331. Hartz AM, Bauer B, Fricker G, Miller DS. 2006. Rapid modulation of P-glycoprotein-
mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and
lipopolysaccharide. Mol Pharmacol 69:462-470.